28BIO (AXOSIM)

Company Snapshot

Founded: 2014
Entity Type: Private
Region: U.S.
Headquarter: Los Angeles, U.S.
Key Geographics: U.S.
Corporate Address: 4224 Houma Boulevard, Suite 224 Metairie, Los Angeles 70006, U.S. Tel: +1-504-609-3469 www.28bio.com

Company Overview

AxoSim, a spin-off of Tulane University in 2014, developed proprietary technology for a brain-on-a-chip in vitro model. The platform is developed by combining neural interfacing, artificial intelligence, and tissue engineering technologies. AxoSim’s biomimetic platforms help fasten the development of CNS drugs to combat diseases, including multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, and other neurological disorders. AxoSim's brain-on-a-chip models exhibit over 90% accuracy in evaluating human outcomes compared to 30% in animal models.

28BIO (AXOSIM) In Reports

Organ-on-a-Chip: Global Markets

BCC Research Report: Dive into organ on a chip market report includes global revenue for base year data of 2023 and estimated data for the forecast period 2024 through 2029.

Laboratory Animal Models, 3D Cultures and Organoids: Global Markets

BCC Research Market Report for Laboratory Animal Models, 3D Cultures and Organoids Market. Global market for organoids is estimated to increase from $1.4 billion in 2022 to reach $3.7 billion by 2027 with a CAGR of...

Organ-on-a-Chip: Global Markets

BCC Research Market Report for organ-on-a-chip market should reach $183.4 million by 2026 from $32.0 million in 2021 at a compound annual growth rate (CAGR) of 41.8%

Company's Business Segments

  • Products : CNS-3D Brain Organoids, CNS-3D Inflammatory Organoids, CNS-3D Myelinated Organoids, CNS-3D Alzheimer's Model
  • Services : CNS-3D Services, PNS-3D Services, Others

Applications/End User Industries

  • Healthcare
  • Pharmaceutical
  • Biotechnology
  • Life Sciences
AI Sentiment